Are Pharma Companies Too Big to Innovate?

Does size matter when it comes to innovation in the pharmaceutical industry?

Jan 2, 2014 at 2:33PM

Ask any investor what they think about Johnson & Johnson (NYSE:JNJ), and you'll probably hear that it's a diversified pharma company, a blue-chip stock that pays a hefty dividend, and it's a relatively safe investment for investors looking for exposure to the health-care sector. But you might also hear investors criticize its size. With a market cap of almost $260 billion, Johnson & Johnson is one of the largest companies in the U.S., and it edges out both Merck and Pfizer as the largest pharma company in the Dow. Can a company this massive be nimble and entrepreneurial enough to innovate? Is its size holding back its long-term potential to bring new products to market?

Looking at Johnson & Johnson's stellar performance in 2013 and its growing pharmaceutical division, size doesn't seem to be a problem here. In fact, Bernard Munos, innovation expert and founder of the InnoThink Center for Research in Biomedical Innovation, doesn't believe that it's impossible for a large company to innovate. He thinks investors are better served looking at a company's culture and leadership, citing historical examples from Merck and Roche's subsidiary Genentech. In the following interview, Munos further explains why size doesn't matter when it comes to innovation. A transcript follows the video.

The Motley Fool's top stock pick for 2014
The market stormed out to huge gains across 2013, leaving investors on the sidelines burned. However, opportunistic investors can still find huge winners. The Motley Fool's chief investment officer has just hand-picked one such opportunity in our new report: "The Motley Fool's Top Stock for 2014." To find out which stock it is and read our in-depth report, simply click here. It's free!

Max Macaluso: Bernard, we've been talking a lot about innovation, companies that have embraced it in the Big Pharma industry. I'm curious, is it possible to be too big to innovate? Do you look at a company like Johnson & Johnson, for instance; its market cap is enormous. You look at Merck. Merck is so diversified -- they do pharmaceuticals, consumer health, also animal health -- is it difficult to innovate when you're that big? Is it impossible to innovate when you're that large?

Bernard Munos: It's not. But you've got to keep in mind that, when it comes to innovation, the critical mass is one human brain. It's not 1,000 people. It's one human brain. This is why Rockefeller does it so well. They've got 75 outstanding brains that spin out one Nobel Prize after the other.

I think the pharmaceutical industry over the last 15 years, certainly the large companies, have tended to forget that. In fact, they have purged their "mad scientists," so to speak, because those people tend to be tough to manage, because they always have a different idea.

The leaders of the industry fail to recognize that this is the critical ingredient that you need in order to spur innovation, so they got rid of them and they ended up with lots of people that were easier to manage, but didn't produce anything; hence, this industrywide innovation crisis.

Look at Merck when Vagelos was managing it. It was a big company, one of the biggest ones in the industry, and yet it performed extremely well. At $100 billion market cap, Genentech was not small, and yet it kept coming with one breakthrough after the other.

It's all about leadership. I think wherever you have effective leadership, size doesn't matter. You can have an innovative culture and organization that will produce breakthroughs. If the leadership isn't there, you're not going to get that. It doesn't matter how much money you throw at it, it doesn't matter the processes that you've got. It doesn't matter how many times you reorganize the organization. It just isn't going to work.

Max Macaluso, Ph.D. and Bernard Munos have no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at www.fool.com/podcasts.

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to www.fool.com/podcasts, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.

 


Compare Brokers